Table 2.
Effects of chronic juvenile CBDV administration on the RNA expression of plasticity and inflammatory brain markers (Study 2).
| Brain Region | Brain Marker | CHRONIC TREATMENT AT WEANING | ||||||
|---|---|---|---|---|---|---|---|---|
| VEH | CBDV-20 | CBDV-100 | Significant Differences | |||||
| WT | KO | WT | KO | WT | KO | |||
| CA1 | BDNF | 1.00 ± 0.04 | 1.02 ± 0.03 | 1.13 ± 0.06 | 1.15 ± 0.06 | 0.90 ± 0.05 | 1.12 ± 0.09 | |
| IL-10 | 1.96 ± 0.77 | 1.28 ± 0.52 | 0.55 ± 0.25 | 2.54 ± 1.08 | 2.36 ± 1.22 | 0.78 ± 0.41 | ||
| IL-1β | 1.43 ± 0.40 | 1.11 ± 0.42 | 0.59 ± 0.19 | 1.73 ± 0.54 | 1.88 ± 0.75 | 0.63 ± 0.23 | ||
| IL-6 | 1.90 ± 0.65 | 1.17 ± 0.52 | 0.34 ± 0.12 | 2.06 ± 0.77 | 2.29 ± 1.21 | 0.76 ± 0.36 | ||
| CD11b | 1.01 ± 0.07 | 1.02 ± 0.05 | 1.00 ± 0.06 | 1.04 ± 0.07 | 0.84 ± 0.08 | 0.99 ± 0.08 | ||
| CD45 | 1.12 ± 0.22 | 1.09 ± 0.27 | 0.80 ± 0.16 | 1.28 ± 0.30 | 1.35 ± 0.38 | 0.79 ± 0.10 | ||
| TNF-α | 1.75 ± 0.69 | 1.17 ± 0.49 | 0.33 ± 0.11 | 1.93 ± 0.72 | 2.08 ± 1.07 | 1.23 ± 0.61 | ||
| CA3 | BDNF | 1.03 ± 0.11 | 0.96 ± 0.04 | 1.09 ± 0.06 | 1.09 ± 0.05 | 1.04 ± 0.07 | 0.94 ± 0.05 | |
| IL-10 | 0.87 ± 0.29 | 1.97 ± 0.76 | 4.57 ± 1.83 | 4.95 ± 2.04 | 6.54 ± 2.85 | 0.79 ± 0.19 | ||
| IL-1β | 1.02 ± 0.46 | 2.17 ± 0.76 | 2.74 ± 0.81 | 3.22 ± 1.30 | 3.53 ± 1.34 | 0.89 ± 0.11 | ||
| IL-6 | 2.59 ± 1.35 | 3.47 ± 1.17 | 4.14 ± 1.38 | 6.36 ± 2.27 | 4.90 ± 2.17 | 1.41 ± 0.38 | ||
| CD11b | 1.01 ± 0.05 | 0.99 ± 0.04 | 1.26 ± 0.03 | 1.24 ± 0.07 | 1.13 ± 0.04 | 1.11 ± 0.03 | Overall treatment effect (CBDV-100 and CBDV-20 > VEH) | |
| CD45 | 1.10 ± 0.21 | 1.14 ± 0.12 | 1.26 ± 0.15 | 1.51 ± 0.33 | 1.18 ± 0.22 | 0.80 ± 0.10 | ||
| TNF-α | 1.78 ± 0.80 | 1.74 ± 0.60 | 3.25 ± 1.12 | 3.12 ± 1.33 | 4.83 ± 2.26 | 0.59 ± 0.18 | ||
| DG | BDNF | 1.01 ± 0.07 | 1.14 ± 0.06 | 1.05 ± 0.05 | 1.11 ± 0.07 | 1.05 ± 0.04 | 1.04 ± 0.05 | |
| IL-10 | 0.77 ± 0.17 | 1.43 ± 0.21 | 2.42 ± 0.87 | 0.77 ± 0.15 | 1.19 ± 0.24 | 1.08 ± 0.19 | ||
| IL-1β | 1.03 ± 0.11 | 1.10 ± 0.14 | 1.31 ± 0.28 | 0.95 ± 0.10 | 1.25 ± 0.24 | 1.19 ± 0.25 | ||
| IL-6 | 1.11 ± 0.22 | 1.07 ± 0.19 | 1.71 ± 0.32 | 1.59 ± 0.30 | 1.97 ± 0.36 | 1.31 ± 0.23 | ||
| CD11b | 1.01 ± 0.07 | 0.97 ± 0.05 | 0.91 ± 0.06 | 0.95 ± 0.04 | 0.99 ± 0.04 | 1.13 ± 0.03 | Overall treatment effect (CBDV-100 > CBDV-20) | |
| CD45 | 1.07 ± 0.16 | 1.14 ± 0.12 | 1.06 ± 0.06 | 1.19 ± 0.09 | 1.56 ± 0.15 | 1.35 ± 0.13 | Overall treatment effect (CBDV100 > CBDV-20 and VEH) | |
| TNF-α | 0.82 ± 0.09 | 1.37 ± 0.13 | 1.20 ± 0.15 | 0.97 ± 0.21 | 1.56 ± 0.36 | 1.44 ± 0.47 | ||
| PFC | BDNF | 1.02 ± 0.08 | 1.00 ± 0.11 | 1.17 ± 0.11 | 1.26 ± 0.13 | 0.90 ± 0.07 | 0.92 ± 0.17 | Overall treatment effect (CBDV-100 < CBDV-20) |
| IL-10 | 1.36 ± 0.37 | 1.31 ± 0.35 | 1.45 ± 0.26 | 1.17 ± 0.46 | 1.34 ± 0.31 | 1.62 ± 0.75 | ||
| IL-1β | 1.05 ± 0.13 | 1.05 ± 0.21 | 1.07 ± 0.17 | 0.86 ± 0.12 | 1.09 ± 0.19 | 1.43 ± 0.29 | ||
| IL-6 | 1.47 ± 0.47 | 1.47 ± 0.38 | 0.71 ± 0.12 | 1.07 ± 0.25 | 1.05 ± 0.17 | 3.15 ± 1.23 | ||
| CD11b | 1.12 ± 0.05 | 0.90 ± 0.05 | 1.11 ± 0.06 | 1.06 ± 0.08 | 1.01 ± 0.06 | 1.05 ± 0.12 | ||
| CD45 | 1.23 ± 0.31 | 0.92 ± 0.14 | 1.22 ± 0.10 | 1.08 ± 0.11 | 1.44 ± 0.18 | 1.41 ± 0.25 | ||
| TNF-α | 1.39 ± 0.42 | 0.98 ± 0.22 | 0.70 ± 0.13 | 1.02 ± 0.36 | 1.38 ± 0.37 | 0.88 ± 0.09 | ||
mRNA quantification was performed by RT-qPCR analysis. The relative level of expression was calculated with the comparative (2−ΔΔCT) method [51]. Data refer to bold change and are expressed as mean ± SEM. Sample size for each group was 7–9. Statistically significant differences are highlighted in yellow. CA1 = hippocampal CA1 subfield; CA3 = hippocampal CA3 subfield; DG = dentate gyrus; PFC = prefrontal cortex.